Passive and Active Tumor Targeting in Photodynamic Therapy of Cancer: Mini-Review

Blassan P. George orcid
University of Johannesburg, South Africa

Heidi Abrahamse orcid (Login required)
University of Johannesburg, South Africa


Paper #9100 received 15 Apr 2024; revised manuscript received 28 May 2024; accepted for publication 4 Jun 2024; published online 3 Aug 2024.

DOI: 10.18287/JBPE24.10.040201

Abstract

Photodynamic therapy (PDT) is a minimally invasive treatment procedure that utilizes a light of specific wavelength and a chemically nontoxic drug photosensitizer (PS) to generate reactive oxygen species (ROS) that can selectively destroy cancer cells or other targeted tissues. However, to increase the efficiency and application of PDT, several issues still need to be resolved. One of the main challenges in PDT is ensuring that the photosensitizing agent accumulates specifically in cancer cells and not in healthy tissues. This is particularly challenging for solid tumors, which have a complex microenvironment and poor vascularization. Passive and active targeting are two strategies in PDT that aim to improve treatment outcomes by enhancing the selective accumulation of PS in tumors thereby improving the cancer therapeutic outcome. These strategies play a critical role in optimizing the efficacy and safety of PDT for cancer treatment. Passive and active targeting strategies have their advantages and limitations. In this mini-review, we focus on the advantages and disadvantages of each method and discuss the role of stimuli-responsive changes in PS delivery.

Keywords

passive and active targeting; photosensitizers; photodynamic therapy; stimuli-response; cancer

Full Text:

PDF

References


1. The Lancet, “GLOBOCAN 2018: counting the toll of cancer,” The Lancet 392(10152), 985 (2018).

2. H. Abrahamse, M. R. Hamblin, “New photosensitizers for photodynamic therapy,” Biochemical Journal 473(4), 347–364 (2016).

3. K. Moloudi, H. Abrahamse, and B. P. George, “Photodynamic therapy induced cell cycle arrest and cancer cell synchronization: review,” Frontiers in Oncology 13, 1225694 (2023).

4. K. Moloudi, P. Sarbadhikary, H. Abrahamse, and B. P. George, “Understanding the Photodynamic Therapy Induced Bystander and Abscopal Effects: A Review,” Antioxidants 12(7), 1434 (2023).

5. M. M. Van Veen, J. J. S. Kooij, A. M. Boonstra, M. C. M. Gordijn, and E. J. W. Van Someren, “Delayed Circadian Rhythm in Adults with Attention-Deficit/Hyperactivity Disorder and Chronic Sleep-Onset Insomnia,” Biological Psychiatry 67(11), 1091–1096 (2010).

6. B. Ortel, C. R. Shea, and P. Calzavara-Pinton, “Molecular mechanisms of photodynamic therapy,” Frontiers in Bioscience 14(11), 4157−4172 (2009).

7. D. Sharma, S. Singh, P. Kumar, G. K. Jain, G. Aggarwal, W. H. Almalki, and P. Kesharwani, “Mechanisms of photodynamic therapy,” Chapter 2 in Nanomaterials for Photodynamic Therapy, P. Kesharwani (Ed.), Elsevier, 41–54 (2023).

8. L. B. Josefsen, R. W. Boyle, “Photodynamic therapy: novel third-generation photosensitizers one step closer?,” British Journal of Pharmacology 154(1), 1−3 (2008).

9. N. Plekhova, O. Shevchenko, O. Korshunova, A. Stepanyugina, I. Tananaev, and V. Apanasevich, “Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy,” Bioengineering 9(2), 82 (2022).

10. H. O. Alsaab, M. S. Alghamdi, A. S. Alotaibi, R. Alzhrani, F. Alwuthaynani, Y. S. Althobaiti, A. H. Almalki, S. Sau, and A. K. Iyer, “Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine,” Cancers 12(10), 2793 (2020).

11. M. Lan, S. Zhao, W. Liu, C. Lee, W. Zhang, and P. Wang, “Photosensitizers for Photodynamic Therapy,” Advanced Healthcare Materials 8(13), 1900132 (2019).

12. H. Montaseri, C. A. Kruger, and H. Abrahamse, “Review: Organic nanoparticle based active targeting for photodynamic therapy treatment of breast cancer cells,” Oncotarget 11(22), 2120–2136 (2020).

13. W. T. Li, “Nanotechology-based strategies to enhance the efficacy of photodynamic therapy for cancers,” Current Drug Metabolism 10(8), 851−860 (2009).

14. A. M. Bugaj, “Targeted photodynamic therapy — a promising strategy of tumor treatment,” Photochemical & Photobiological Sciences 10(7), 1097–1109 (2011).

15. A. Narmani, R. Jahedi, E. Bakhshian-Dehkordi, S. Ganji, M. Nemati, R. Ghahramani-Asl, K. Moloudi, S. M. Hosseini, H. Bagheri, P. Kesharwani, A. Khani, B. Farhood, and A. Sahebkar, “Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy,” Expert Opinion on Drug Delivery 20(7), 937–954 (2023).

16. Y.-C. Lin, Z.-R. Lin, L.-W. Tsai, E. Perevedentseva, A. Karmenyan, and C.-L. Cheng, “Spectral Analysis of Nanodiamond-Berberine Complex Interaction with Living Cells for Nanoparticle Mediated Drug Delivery,” Journal of Biomedical Photonics & Engineering 3(1), 010305 (2017).

17. A. Agrawal, S. Rellegadla, and S. Jain, “Biomedical applications of PLGA particles,” Chapter 4 in Materials for Biomedical Engineering, A.-M. Holban, A. M. Grumezescu (Eds.), Elsevier, 87–129 (2019).

18. M. R. Gigliobianco, C. Casadidio, R. Censi, and P. Di Martino, “Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability,” Pharmaceutics 10(3), 134 (2018).

19. N. A. Charoo, Z. Rahman, and M. A. Khan, “Nanoparticles for improvement in oral bioavailability,” Chapter 11 in Nanoarchitectonics in Biomedicine, A. M. Grumezescu (Ed.), Elsevier, 371–410 (2019).

20. N. C. Shinde, N. J. Keskar, and P. D. Argade, “Nanoparticles: Advances in drug delivery systems,” Research Journal of Pharmaceutical, Biological and Chemical Sciences 3(1), 922−929 (2012).

21. D. Mishra, J. R. Hubenak, and A. B. Mathur, “Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy,” Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials 101(12), 3646–3660 (2013).

22. A. Z. Wilczewska, K. Niemirowicz, K. H. Markiewicz, and H. Car, “Nanoparticles as drug delivery systems,” Pharmacological Reports 64(5), 1020–1037 (2012).

23. L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, and S. Yang, “Small molecules in targeted cancer therapy: advances, challenges, and future perspectives,” Signal Transduction and Targeted Therapy 6(1), 201 (2021).

24. S. Parveen, R. Misra, and S. K. Sahoo, “Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging,” Nanomedicine: Nanotechnology, Biology and Medicine 8(2), 147−166 (2012).

25. Y. Herdiana, N. Wathoni, S. Shamsuddin, I. M. Joni, and M. Muchtaridi, “Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment,” Polymers 13(11), 1717 (2021).

26. K. Moloudi, A. Khani, M. Najafi, R. Azmoonfar, M. Azizi, H. Nekounam, M. Sobhani, S. Laurent, and H. Samadian, “Critical parameters to translate gold nanoparticles as radiosensitizing agents into the clinic,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 15(6), e1886 (2023).

27. M. F. Attia, N. Anton, J. Wallyn, Z. Omran, and T. F. Vandamme, “An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites,” Journal of Pharmacy and Pharmacology 71(8), 1185–1198 (2019).

28. V. Torchilin, “Tumor delivery of macromolecular drugs based on the EPR effect,” Advanced Drug Delivery Reviews 63(3), 131–135 (2011).

29. X. Wang, S. Li, Y. Shi, X. Chuan, J. Li, T. Zhong, H. Zhang, W. Dai, B. He, and Q. Zhang, “The development of site-specific drug delivery nanocarriers based on receptor mediation,” Journal of Controlled Release 193, 139–153 (2014).

30. A. Stallivieri, L. Colombeau, G. Jetpisbayeva, A. Moussaron, B. Myrzakhmetov, P. Arnoux, S. Acherar, R. Vanderesse, and C. Frochot, “Folic acid conjugates with photosensitizers for cancer targeting in photodynamic therapy: Synthesis and photophysical properties,” Bioorganic & Medicinal Chemistry 25(1), 1–10 (2017).

31. S. Yan, Q. Huang, J. Chen, X. Song, Z. Chen, M. Huang, P. Xu, and J. Zhang, “Tumor-targeting photodynamic therapy based on folate-modified polydopamine nanoparticles,” International Journal of Nanomedicine 14, 6799−6812 (2019).

32. G. Yi, S. H. Hong, J. Son, J. Yoo, C. Park, Y. Choi, and H. Koo, “Recent advances in nanoparticle carriers for photodynamic therapy,” Quantitative Imaging in Medicine and Surgery 8(4), 433–443 (2018).

33. J. Son, D. Lee, J. Yoo, C. Park, and H. Koo, “A comparative study of the effect of drug hydrophobicity on nanoparticle drug delivery in vivo using two photosensitizers,” Nanomedicine: Nanotechnology, Biology and Medicine 24, 102151 (2020).

34. R. A. Petros, J. M. DeSimone, “Strategies in the design of nanoparticles for therapeutic applications,” Nature Reviews Drug Discovery 9(8), 615–627 (2010).

35. R. H. Fang, C.-M. J. Hu, K. N. H. Chen, B. T. Luk, C. W. Carpenter, W. Gao, S. Li, D.-E. Zhang, W. Lu, and L. Zhang, “Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles,” Nanoscale 5(19), 8884 (2013).

36. J. D. Byrne, T. Betancourt, and L. Brannon-Peppas, “Active targeting schemes for nanoparticle systems in cancer therapeutics,” Advanced Drug Delivery Reviews 60(15), 1615–1626 (2008).

37. Y. Zhang, Y. Wan, Y. Chen, N. T. Blum, J. Lin, and P. Huang, “Ultrasound-Enhanced Chemo-Photodynamic Combination Therapy by Using Albumin “Nanoglue”-Based Nanotheranostics,” ACS Nano 14(5), 5560–5569 (2020).

38. H. Gong, Y. Chao, J. Xiang, X. Han, G. Song, L. Feng, J. Liu, G. Yang, Q. Chen, and Z. Liu, “Hyaluronidase To Enhance Nanoparticle-Based Photodynamic Tumor Therapy,” Nano Letters 16(4), 2512–2521 (2016).

39. C. Naidoo, C. A. Kruger, and H. Abrahamse, “Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells,” Oncotarget 10(58), 6079–6095 (2019).

40. J. Yoo, C. Park, G. Yi, D. Lee, and H. Koo, “Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems,” Cancers 11(5), 640 (2019).

41. T. Qi, B. Chen, Z. Wang, H. Du, D. Liu, Q. Yin, B. Liu, Q. Zhang, and Y. Wang, “A pH-Activatable nanoparticle for dual-stage precisely mitochondria-targeted photodynamic anticancer therapy,” Biomaterials 213, 119219 (2019).

42. N. Iqbal, N. Iqbal, “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications,” Molecular Biology International 2014, 1–9 (2014).

43. J. Kovaľ, J. Mikeš, R. Jendželovský, M. Kello, P. Solár, and P. Fedoročko, “Degradation of HER2 Receptor Through Hypericin-mediated Photodynamic Therapy,” Photochem & Photobiology 86(1), 200−205 (2010).

44. H. J. Hah, G. Kim, Y. K. Lee, D. A. Orringer, O. Sagher, M. A. Philbert, and R. Kopelman, “Methylene Blue-Conjugated Hydrogel Nanoparticles and Tumor-Cell Targeted Photodynamic Therapy,” Macromolecular Bioscience 11(1), 90−99 (2011).

45. L. Zeng, Y. Pan, Y. Tian, X. Wang, W. Ren, S. Wang, G. Lu, and A. Wu, “Doxorubicin-loaded NaYF4:Yb/Tm–TiO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers,” Biomaterials 57, 93–106 (2015).

46. A. I. Gavrina, M. V. Shirmanova, N. A. Aksenova, D. V. Yuzhakova, L. B. Snopova, A. B. Solovieva, P. S. Тimashev, V. V. Dudenkova, and E. V. Zagaynova, “Photodynamic therapy of mouse tumor model using chlorin e6- polyvinyl alcohol complex,” Journal of Photochemistry and Photobiology B: Biology 178, 614–622 (2018).

47. D. Lee, S. Kwon, S. Jang, E. Park, Y. Lee, and H. Koo, “Overcoming the obstacles of current photodynamic therapy in tumors using nanoparticles,” Bioactive Materials 8, 20–34 (2022).

48. S. Moghassemi, A. Dadashzadeh, R. B. Azevedo, O. Feron, and C. A. Amorim, “Photodynamic cancer therapy using liposomes as an advanced vesicular photosensitizer delivery system,” Journal of Controlled Release 339, 75–90 (2021).

49. S. Md, S. Haque, T. Madheswaran, F. Zeeshan, V. S. Meka, A. K. Radhakrishnan, and P. Kesharwani, “Lipid based nanocarriers system for topical delivery of photosensitizers,” Drug Discovery Today 22(8), 1274–1283 (2017).

50. S. Marchal, G. Dolivet, H.-P. Lassalle, F. Guillemin, and L. Bezdetnaya, “Targeted photodynamic therapy in head and neck squamous cell carcinoma: heading into the future,” Lasers in Medical Science 30(9), 2381–2387 (2015).

51. J. C. S. Simões, S. Sarpaki, P. Papadimitroulas, B. Therrien, and G. Loudos, “Conjugated Photosensitizers for Imaging and PDT in Cancer Research,” Journal of Medicinal Chemistry 63(23), 14119–14150 (2020).

52. A. Dhaliwal, G. Zheng, “Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery,” Theranostics 9(26), 8091–8108 (2019).

53. A. Gumala, S. Sutriyo, “Active Targeting Gold Nanoparticle for Chemotherapy Drug Delivery: A Review,” Pharmaceutical Sciences 28(3), 342−354 (2021).

54. L. Lin, L. Xiong, Y. Wen, S. Lei, X. Deng, Z. Liu, W. Chen, and X. Miao, “Active Targeting of Nano-Photosensitizer Delivery Systems for Photodynamic Therapy of Cancer Stem Cells,” Journal of Biomedical Nanotechnology 11(4), 531–554 (2015).

55. O. C. Didamson, R. Chandran, and H. Abrahamse, “A Gold Nanoparticle Bioconjugate Delivery System for Active Targeted Photodynamic Therapy of Cancer and Cancer Stem Cells,” Cancers 14(19), 4558 (2022).

56. M. A. Rahim, N. Jan, S. Khan, H. Shah, A. Madni, A. Khan, A. Jabar, S. Khan, A. Elhissi, Z. Hussain, H. C. Aziz, M. Sohail, M. Khan, and H. E. Thu, “Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting,” Cancers 13(4), 670 (2021).

57. J. Tian, C. Xiao, B. Huang, C. Wang, and W. Zhang, “Janus macromolecular brushes for synergistic cascade-amplified photodynamic therapy and enhanced chemotherapy,” Acta Biomaterialia 101, 495–506 (2020).

58. W. Yu, R. Liu, Y. Zhou, and H. Gao, “Size-Tunable Strategies for a Tumor Targeted Drug Delivery System,” ACS Central Science 6(2), 100–116 (2020).

59. G. Yang, S. Z. F. Phua, W. Q. Lim, R. Zhang, L. Feng, G. Liu, H. Wu, A. K. Bindra, D. Jana, Z. Liu, and Y. Zhao, “A Hypoxia-Responsive Albumin-Based Nanosystem for Deep Tumor Penetration and Excellent Therapeutic Efficacy,” Advanced Materials 31(25), 1901513 (2019).

60. Z. Liu, T. Cao, Y. Xue, M. Li, M. Wu, J. W. Engle, Q. He, W. Cai, M. Lan, and W. Zhang, “Self-Amplified Photodynamic Therapy through the 1O2 -Mediated Internalization of Photosensitizers from a Ppa-Bearing Block Copolymer,” Angewandte Chemie International Edition 59(9), 3711−3717 (2020).




Bookmark and Share


Сontact

34 Moskovskoe shosse, Samara, 443086, Russian Federation
Email: j-bpe@ssau.ru
Phone: +7-846-267-4550
© 2014-2025 J-BPE